Clinical and epidemiological studies have confirmed the role of the TM6SF2 variant in the development of MAFLD (Xue et al., 2022), and TM6SF2 has also been shown to play an important role in promoting liver fibrosis and hepatocellular carcinoma in mouse models (Luo et al., 2022a). The gene discussed is TM6SF2; the disease is hepatocellular carcinoma.